Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Need to know what going on
Low float
Inside buying earlier today and this week
And results of Phase 2 coming earlier then expected with good results
Well this the rumors anyhow
I’m shorting garbage like CRIS
I have too much puts on CRIS
Hopefully I’m right with my gambling picks
15 % already short , squeeze tomorrow maybe 6 + bucks
So what are the chances this becomes the most shorted stock at these prices?
* * $VTVT Video Chart 10-29-2020 * *
Link to Video - click here to watch the technical chart video
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D
Email Print Friendly Share
September 23, 2020 07:30 ET | Source: vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) yesterday presented data from the completed Phase 2 Simplici-T1 study (NCT03335371) that support the clinical potential of TTP399 as an oral adjunctive therapy in type 1 diabetes (T1D). Newly reported data provide additional evidence suggesting that TTP399 does not increase the risk of diabetic ketoacidosis (DKA), a serious and potentially life-threatening complication that occurs in patients with T1D, due to its unique mechanism of action. DKA is a known side-effect and shortcoming of several investigational oral therapies that have been advanced for T1D, and TTP399’s positive impact on ketone levels is a point of important differentiation. The company also presented additional data from the Simplici-T1 study confirming that treatment with TTP399 resulted in significant improvements in HbA1c, with reduction in bolus insulin dose, without increasing the risk of hypoglycemia or DKA.
“The data presented at EASD add to the growing body of evidence supporting the potential of TTP399 to meet the urgent yet still unmet need for an adjunctive therapy for patients living with T1D that improves disease management and health outcomes,” said Steve Holcombe, president and CEO of vTv Therapeutics. “The development of adjunctive oral therapies for T1D has been limited by unacceptable rates of hypoglycemia and ketoacidosis, so the absence of these events in the Simplici-T1 study is an important advance not only for vTv Therapeutics but for the T1D research community as a whole. This body of evidence provides a robust foundation on which to initiate our first pivotal study of TTP399, which we expect will commence by the end of 2020.”
The data was presented in two oral presentations at the 56th Annual Meeting of the European Association for the Study of Diabetes, which is being held virtually September 21-25, 2020, and are available for download at https://vtvtherapeutics.com/pipeline/ttp399/.
“People with T1D are dependent on insulin for survival, yet are unable to achieve the recommended glycemic targets or avoid long-term complications with current insulin regimens,” said Esther Latres, Ph.D., Assistant Vice President of Research at JDRF, which provided funding to support the Simplici-T1 study. “An adjunctive therapy that could enhance glucose control, reduce the need for insulin, and improve long-term health outcomes would transform the lives of individuals living with T1D. We believe that these data support the continued development of TTP399 as an oral adjunctive therapy in this population, and look forward to seeing the results from the planned pivotal trial.”
EASD Virtual Presentation Information
Oral Presentation Title: “The Simplici-T1 Trial: Activation of Glucokinase by TTP399 Improves Glycaemic Control in Patients with Type 1 Diabetes”
Presentation Number: 50
Category: OP 09 Novel Agents in Type 1 Diabetes
Date and Time: Tuesday, September 22, 2020, 8:45 AM - 9:00 AM ET
Oral Presentation Title: “Mechanism Matter: Preliminary Evidence That Activation of Glucokinase by TTP399 Does Not Increase Plasma or Urine Ketones in Type 1 Diabetes”
Presentation Number: 51
Category: OP 09 Novel Agents in Type 1 Diabetes
Date and Time: Tuesday, September 22, 2020, 9:00 AM - 9:15 AM ET
About the Simplici-T1 Study
Simplici-T1 was a multi-center, randomized, double-blind, adaptive study assessing the safety and efficacy of TTP399 as an adjunct to insulin therapy in adults with T1D. The primary endpoint was the change in HbA1c at week 12. The study was conducted with support from JDRF, the leading global organization funding research in type 1 diabetes.
This Phase 2 learn-and-confirm study was conducted in two parts under a treat-to-target protocol to evaluate the safety and efficacy of TTP399 in T1D patients over 12 weeks of daily dosing following a multi-week insulin optimization and placebo run-in period. Part 1 enrolled 19 patients on both insulin pumps and CGMs. The positive topline results from the learning phase - Part 1 were reported in June 2019. The confirming phase, Part 2, enrolled 85 patients that used either insulin pumps or multiple daily injections of insulin; CGMs were allowed for those patients using the devices for at least three months prior to the start of the study.
About Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, and—at present—nothing you can do to cure it.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimer’s disease, and inflammatory disorders. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), and genetic mitochondrial diseases. For more information, please visit www.vtvtherapeutics.com or follow us on Twitter: @vTvTherapeutics.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements.
Contacts
Investors:
Corey Davis
LifeSci Advisors
CDavis@LifeSciAdvisors.com
or
Media:
Glenn Silver
Lazar FINN Partners
646-871-8485
gsilver@lazarpartners.com
Related Articles
More articles issued by vTv Therapeutics Inc.
More articles related to:
Calendar of Events
* * $VTVT Video Chart 07-27-2020 * *
Link to Video - click here to watch the technical chart video
VTVT
Float 10.4M Shares
Outstanding 67.8M
Institutions Holding Shares 26
Held by Institutions 12.37%
OTCMarkets is a better source, and they have it at 42,168,522
https://www.otcmarkets.com/stock/VTVT/security
Shrinkin' volume and pps stabilizin' in this 1.60-1.70 range, a nice update/vol influx would send it above 2.05 again, low floatah for sure imo, hard to predict the turnin' point in these difficult times though, everyone be safe, take care of each other, regards from the Old Continent, ANT
Glad to see the sell off doesn't include VTVT
Finviz shows 3.8 mil float Ihub shows 66 mil Whos telling the truth? https://finviz.com/quote.ashx?t=VTVT&ty=c&p=d&b=1
* * $VTVT Video Chart 02-21-2020 * *
Link to Video - click here to watch the technical chart video
Didn't read it but it must be great news
Putting on my space suit n gravity boots hope to fly. GLTA
this is going to take off on the type 1 news
$$$$$$$$$$$$$$$$$$$$$ VTVT $$$$$$$$$$$$$$$$$$$$$$
New Tweet....
We are excited to be featured in an article from @Vantageanalysis highlighting both our recent positive clinical trial in type 1 diabetes and our ongoing Alzheimer’s study. We think it’s worth a read! https://t.co/uEaRSmHgB0 pic.twitter.com/5f64aLZdDa
— vTv Therapeutics (@vTvTherapeutics) February 17, 2020
VTVT Above VWAP nearing breakout point on Resistance
Break $3.35 and " Off To The Races " Bigly!
$VTVT
* * $VTVT Video Chart 02-10-2020 * *
Link to Video - click here to watch the technical chart video
Just opened a position here today. Going to go long on this one. Hopefully it works out.
VTVT UP 56% RISING.. ,Nice pull back for entry before Lunch Buyers push higher. Yahoo Target $6.50 Current $3.12 up 47%
" vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
GlobeNewswire GlobeNewswire•February 10, 2020 "
https://finance.yahoo.com/news/vtv-therapeutics-announces-positive-results-120010210.html
$6.50 Yahoo Target
https://finance.yahoo.com/quote/VTVT?p=VTVT
$VTVT
Any clue what the FDA process takes in time?
Yes. I would have loved to be able to sell half my shares PreMarket. It hit $4.00
intraday - $3 base, and from here (3.20ish) $3.10 has to hold, otherwise it might shake out to 2.80.
Waiting on solid support to enter
Dunno. In general, when there's a big gap up pre-market, the smart money sells before open.
Surprised it’s this quiet here. Good! Rock on VTVT bottom resistance line? not pushing Upper anymore @ 4
Awesome gap-up...
News:
vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
GlobeNewswire GlobeNewswire•February 10, 2020
- TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis
- Company to host investor conference call today at 8:30 a.m. ET
HIGH POINT, N.C., Feb. 10, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D). TTP399 is a novel, liver-selective glucokinase activator taken once a day. The 12-week trial investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 people with type 1 diabetes on optimized insulin therapy. The study was conducted with support from JDRF International (JDRF), the leading provider of T1D research funding globally.
The trial successfully achieved its primary objective analyzed using two statistical approaches to evaluating the effect of TTP399. The primary statistical analysis evaluated the effect on HbA1c regardless of treatment adherence or notable changes in insulin administration. Under the primary statistical analysis, the trial achieved its primary objective by demonstrating statistically significant improvements in HbA1c (long-term blood sugar) for TTP399 compared to placebo at week 12 (p=0.03).
TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups. The study had no report of diabetic ketoacidosis in either treatment group. There was no incidence of severe hypoglycemia in the treated group and one incident in the placebo group. Patients taking TTP399 experienced fewer symptomatic hypoglycemic episodes: two subjects taking TTP399 reported at least one event compared to eight subjects taking placebo.
“I am very pleased that part 2 of the study confirmed the positive results and effects we saw in part 1. A once-a-day pill that reduces HbA1c and improves time in range with continuous glucose monitoring, without increasing hypoglycemia or any signal for adverse events, is a big win for the future care of type 1 diabetes,” said Dr. John Buse, Director of the North Carolina Translational and Clinical Sciences Institute and of the Diabetes Center at the University of North Carolina School of Medicine and principal investigator for this study.
To eliminate the possibility that the reduction in HbA1c was driven by the administration of excess insulin (3 or more units per day), a second estimand analysis was performed.1 Based upon this analysis, people treated with TTP399 achieved a statistically-significant placebo-subtracted reduction in HbA1c of 0.32% (p=0.001). Patients taking TTP399 experienced a 0.21% reduction in HbA1c, while patients taking placebo experienced a 0.11% increase in HbA1c, from a mean study baseline HbA1c of 7.6% following a multi-week insulin optimization period prior to the administration of study treatment.
Daily Time in Range was improved by approximately two hours in patients treated with TTP399 relative to placebo (p=0.03). TTP399 treatment reduced the total daily mealtime bolus insulin dose by 11% relative to baseline (p=0.02) whereas the placebo-treated group experienced a 3% decrease relative to baseline.
“The development of a safe and effective therapy that improves glucose control is a critical step toward eliminating the dangerous highs and lows associated with type 1 diabetes,” said Sanjoy Dutta, Ph.D., JDRF Vice President of Research. “The results from the Simplici-T1 trial indicate that TTP339 is a promising oral treatment option to help people with type 1 diabetes keep their HbA1c levels within a healthy range, and stay in a desirable glucose range for most of the day, while simplifying the daily management of the disease.”
Despite advances in insulin and its administration, people with T1D continue to have difficulty achieving optimal glucose control (HbA1c of less than 7.0%), warranting the need for adjunctive therapies. TTP399 selectively activates glucokinase (GK), a key regulator of glucose metabolism, in the liver. This activation has been shown to increase glucose utilization, which in turn lowers blood glucose. Simplici-T1 is the first study to test activation of GK in patients with T1D, evaluating daily oral TTP399 as an adjunct to insulin therapy.
“Roughly 1.5 million people in the US are living with type 1 diabetes and the burdensome, around the clock disease management it requires to avoid life-threatening complications. These patients and their families are demanding new treatment options that offer simple, predictable diabetes management to improve HbA1c and time in range. Consistent with FDA guidance, a 0.3% improvement in HbA1c is considered clinically meaningful, and coupled with the well-controlled population of patients and favorable safety data from our clinical trials to date, this provides a strong basis for moving this potential first-in-class program forward,” said Steve Holcombe, President and CEO of vTv Therapeutics. “We intend to engage with the FDA as soon as possible to plan an efficient development pathway for TTP399 and hope to initiate a registration trial this year.”
It depends on the Phase 2 Part 2 Diabetes results that will be released at 7am Monday morning. My guess is with the insider buying the last month it will be good news
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 - Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
4:05 pm ET February 7, 2020 (Globe Newswire) Print
Ty I see now been doing some homework lets see if it gains momo or slides Mon.
Google VTVT news. Up 29% AH.All the business news organizations have stories.
Insider buying the last 3 weeks. I'll be shocked if it isn't good news Monday morning.
Be interested Monday, follow through? What say you?
Jumped to $2.59 afterhours. This is a hold for the long, hopefully they make it out of the clinical stage.
Another 1,250,000 bought by Perelmann. Who knows what he knows.
Last week Ron Perelmann bought 2,000,000 worth of shares. Inside info maybe on phase 2 diabites drug next month?
* * $VTVT Video Chart 01-15-2020 * *
Link to Video - click here to watch the technical chart video
Funny how the price goes up a bit every time investors gets diluted again and again.
No it’s not that Ron Perelman knows something great is about to happen, he has an agreement whereby vTv can place shares with him anytime they need more money to do whatever they are doing and achieving nothing.
Followers
|
38
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
613
|
Created
|
01/03/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |